Kristi M Annecone, FNP
Allergy & Immunology · San Jose
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
On the public record
- Medicare does not list them as allowed to order and refer
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Kristi M Annecone’s office at (408) 243-2700 to ask if they take your plan before you enroll.
Drugs they prescribed that Part D paid
$1,561
Pharmacies billed $1,561 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 14) in 2024. Too few prescriptions to judge: with under about 50 a year, a handful of patients can swing this share.
$1,561 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
Year by year
| 2024 | 14 | None | 0% (0) | None | $1,561 |
| 2020 | 14 | None | 0% (0) | None | $4,252 |
| 2017 | 23 | None | 0% (0) | 48% | $4,033 |
| 2016 | 35 | None | 0% (0) | 63% | $6,295 |
| 2015 | 43 | 11 | 0% (0) | 49% | $6,310 |
| 2014 | 16 | None | 0% (0) | None | $558 |
| 2013 | 44 | None | 0% (0) | 27% | $3,040 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2016: 1 drug
| Advair Diskus | 14 | $4,726 | $338 |
2015: 1 drug
| Advair Diskus | 13 | $3,965 | $305 |
2013: 1 drug
| Montelukast | 12 | $222 | $19 |
Money from drug and device companies
$179 in 2025
| 2025 | 3 | 8 | None | $179 |
| 2024 | 6 | 14 | None | $1,322 |
| 2023 | 2 | 11 | None | $804 |
| 2022 | 3 | 7 | None | $203 |
| 2021 | 5 | 7 | None | $154 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| CSL Behring | Andembry | $96 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Tezspire | $47 | 2 payments
|
| ARS Pharmaceuticals Operations | Neffy | $36 | 2 payments
|
See all 8 published payments
| CSL Behring | Meals · 2025-11-10 | Andembry | $20 |
| CSL Behring | Meals · 2025-10-15 | Hizentra | $39 |
| ARS Pharmaceuticals Operations | Meals · 2025-09-10 | Neffy | $17 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-03 | Tezspire | $24 |
| CSL Behring | Meals · 2025-07-22 | Andembry | $21 |
| ARS Pharmaceuticals Operations | Meals · 2025-04-30 | Neffy | $19 |
| CSL Behring | Meals · 2025-04-15 | Haegarda | $16 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-19 | Tezspire | $23 |
See earlier years (2024, 2023, 2022, 2021)
2024: $1,322
| AstraZeneca Pharmaceuticals LP | Tezspire | $1,172 | 9 payments
|
| Blueprint Medicines | Ayvakit | $42 | 1 payment
|
| Octapharma USA | Cutaquig | $37 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $29 | 1 payment
|
| kaleo | Auvi-Q | $28 | 1 payment
|
| GlaxoSmithKline | Nucala | $14 | 1 payment
|
2023: $804
| AstraZeneca Pharmaceuticals LP | Breztri | $759 | 9 payments
|
| Octapharma USA | Cutaquig | $45 | 2 payments
|
2022: $203
| GlaxoSmithKline | Trelegy Ellipta | $149 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Tezspire | $36 | 2 payments
|
| Teva Pharmaceuticals USA | Airduo Digihaler | $19 | 1 payment
|
2021: $154
| GlaxoSmithKline | Nucala | $68 | 3 payments
|
| Grifols USA | Xembify | $26 | 1 payment
|
| Horizon Therapeutics plc | Actimmune | $25 | 1 payment
|
| kaleo | Auvi-Q | $24 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Cuvitru | $13 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study To Assess the Efficacy, Safety, and Tolerability of Subcutaneous Sar443765 in Adult Participants With Moderate To Severe Asthma · 2024 | This clinician | $2,090 |
| Teva Pharmaceuticals USA, Inc. · A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma · 2025 | This clinician | $263 |
Professional record
- NPI
- 1316038581
- Licence
- CA 490104
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207K00000X (207K00000X)
- Mailing address
- 4050 Moorpark Avenue, San Jose, CA, 95117
- NPI first listed
- 2006-09-27
- NPI last updated
- 2007-09-10
This is when the NPI record was last certified, not a medical board exam.